Reviewed 21 Jul 2026
Completeness Fair (31%)
Invasive Tumor Detection APP
VisiopharmThe “Invasive Tumor Detection (VDS)” APP provide means for distinguishing between invasive tumor and non-invasive tumor based on two serial single-stained slides with the myoepithelial cell nuclear marker p63 in one slide and a cytokeratin (CK) tumor marker, e.g. PCK, in another slide. With VirtualDoubleStaining™ the two slides are combined to include invasive tumor structures and exclude non-invasive tumor structures.
Supported by 1 paper
General Information
Product name
Company
Modality
Main task
Subspeciality
Organ/Specimen source
Not specified
Disease targeted
Specimen type
Not specified
Staining
Stain subtype
Regulatory Information
Pathway:
In Vitro Diagnostic Regulation (IVDR)
Class:
Class C
Not verified by Health AI Register
Scanner Brands Certified for Use (CE-IVD)
Not specified
Scanner Models Certified for Use (CE-IVD)
Not specified
Other certifications
Not specified
Technical Specifications
Patient population age
Not specified
Input
Not specified
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Not specified
Trigger for analysis
Not specified
Processing time
Not specified
Population
Not specified
Viewer systems
Not specified
Market Presence
On market since
Not specified
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Based on
Not specified
First published: Jul 30, 2025 | Last updated: Jul 21, 2026